Showing 651-660 of 1116 results for "".
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- Alon Harris, MS, PhD, Named 2025 Recipient of Robert Ritch Award for Innovation and Excellence in Glaucomahttps://modernod.com/news/alon-harris-named-2025-recipient-of-robert-ritch-award-for-innovation-and-excellence-in-glaucoma/2482778/Alon Harris, MS, PhD, FARVO, has been announced as the 2025 recipient of The Glaucoma Foundation’s (TGF) 'Robert Ritch Award for Innovation and Excellence in Glaucoma.' The award, established in 2008 and named after TGF founder Robert Ritch, MD, honor
- “Dr. Robert Ritch Forum on Medicine of the Future” at World Ophthalmology Congress 2018https://modernod.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/Robert Ritch, MD, Distinguished Chair in Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai will host the “Robert Ritch Forum on Medicine of the Future” at the World Ophthalmology Congress 2018 (WOC2018) in Barcelona, Spain. This is the first time WOC is dedicating an entire fo
- Graybug Vision Appoints Robert Breuil as Chief Financial Officerhttps://modernod.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO. “I am excited to welcome Robert Breuil to the Gray
- LIGHTMED Appoints Lee Walker-Roberts as Global Business Development Directorhttps://modernod.com/news/lightmed-appoints-lee-walker-roberts-as-global-business-development-director/2476484/LIGHTMED announced the appointment of Lee Walker-Roberts as Global Business Development Director, effective immediately. Mr. Walker-Roberts is an experienced leader and executive advisor for high-tech companies ranging from privately-owned start-ups to companies with over $200 million in annual s
- AbbVie Appoints Robert A. Michael as Chief Executive Officerhttps://modernod.com/news/abbvie-appoints-robert-a-michael-as-chief-executive-officer/2482125/AbbVie, the parent company of Allergan, announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez
- Robert Califf Confirmed to Lead FDA for Second Timehttps://modernod.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/The US Senate on Tuesday voted 50 to 46 in favor of confirming President Joe Biden nominee Robert Califf as commissioner of the FDA, a position he previously held under the Obama administration, according to a FiercePharma report.&
- Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Awardhttps://modernod.com/news/dr-louis-r-pasquale-winner-of-the-glaucoma-foundations-2023-robert-ritch-award/2481629/Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma. Created in 2008, the award recognizes the contributions of individuals who have played a significant and unique role in promoting
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste